🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSTEP-HFpEF: semaglutide in heart failure with preserved EF — 6 month update Page 3

STEP-HFpEF: semaglutide in heart failure with preserved EF — 6 month update

dave_SLC Mon, Dec 22, 2025 at 4:05 PM 12 replies 1,022 viewsPage 3 of 3
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Dec 23, 2025 at 9:59 AM#11
Dr.EM_Chicago said:
The dose-response is real but shallow at the top.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

1 1JenMemphis
Reply Quote Save Share Report
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Dec 23, 2025 at 9:21 PM#12
Admin said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.

50 0SaraMom3, Dr.MetabolicMD, RetaRick_CA and 47 others
Reply Quote Save Share Report
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Dec 24, 2025 at 8:43 AM#13
Dr.EM_Chicago said:
The dose-response is real but shallow at the top.

I read this differently from Dr.EM_Chicago, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

49 24DanielChem_CHI, marco_milano, pam_columbus and 46 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DoseLogDan
Member
201
567
Feb 2025
Montana
Dec 24, 2025 at 8:06 PM#14
dave_SLC said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

48 23sophie_paris, mel_PDX, Dr.AddMedPHL and 45 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Dec 25, 2025 at 7:29 AM#15

Moderator note: a couple of off-topic posts removed.

47 22PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register